[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-564662-105":3,"detail-sidebar-cat-1-en-105":81,"doc-detail-564662-en":127},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","adderall-xr-product-monograph-patient-medication-information","ADDERALL XR Product Monograph - Patient Medication Information","","ADDERALL XR (mixed salts amphetamine extended-release capsules) product monograph provides health-professional and patient medication information for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). It includes key label sections such as indications, contraindications, serious warnings and precautions, dosage and administration, missed dose guidance, overdosage, drug interactions, clinical pharmacology, and storage/stability/disposal. The document also lists adverse reactions and clinical trial information for multiple populations, and summarizes scientific sections including pharmaceutical information and non-clinical toxicology.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/adderall-xr-product-monograph-patient-medication-information/564662/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/adderall-xr-product-monograph-patient-medication-information/564662.png","ImageObject",442,249,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-10-12",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is ADdERALL XR indicated for?","Question",{"text":63,"@type":64},"ADDERALL XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (6–12 years), adolescents (13–17 years), and adults (18 years or older).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What key sections does Part I include?",{"text":68,"@type":64},"Part I covers health professional information including indications, contraindications, serious warnings and precautions, dosage and administration, overdosage, warnings and precautions, adverse reactions, drug interactions, clinical pharmacology, and storage/stability/disposal.",{"name":70,"@type":61,"acceptedAnswer":71},"Where can the patient medication information be found in the monograph?",{"text":72,"@type":64},"The table of contents shows a dedicated section titled \"PATIENT MEDICATION INFORMATION\" separate from Part I and Part II.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},564662,1792097033,{"code":4,"msg":82,"data":83},"success",[84,89,94,99,104,109,114,119,124],{"id":85,"doc_module":22,"doc_module_name":25,"category_name":86,"show_sort_weight":87,"slug":88},11,"Presentations",90,"presentations",{"id":90,"doc_module":22,"doc_module_name":25,"category_name":91,"show_sort_weight":92,"slug":93},12,"Resumes",80,"resumes",{"id":95,"doc_module":22,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},14,"Invoices",70,"invoices",{"id":100,"doc_module":22,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},15,"Posters",60,"posters",{"id":105,"doc_module":22,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},16,"Social Media",50,"social-media",{"id":110,"doc_module":22,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},17,"Forms",40,"forms",{"id":115,"doc_module":22,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},18,"Letters",30,"letters",{"id":120,"doc_module":22,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},21,"Paper Templates",5,"papers-templates",{"id":125,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":126},158,"general-158",{"code":4,"msg":82,"data":128},{"doc_id":79,"user_id":129,"nickname":42,"user_avatar":130,"doc_module":22,"category_id":125,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":136,"language":137,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":12,"update_tm":141,"read_time":100},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","PRODUCT MONOGRAPH  \nINCLUDING PATIENT MEDICATION INFORMATION  \nADDERALL XR®  \nmixed salts amphetamine extended-release capsules  \nCapsule  \n5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg Oral  \nCentral Nervous System Stimulant  \nTakeda Canada Inc.  \n22 Adelaide Street West, Suite 3800 Toronto, Ontario  \nM5H 4E3  \nDate of Initial Approval: Jan 23, 2004  \nDate of Revision: Dec 21 , 2020  \nSubmission Control No: 241496  \nADDERALL XR® and ADDERALL® are registered trademarks of Takeda Pharmaceuticals U.S.A. , Inc.  \nTAKEDA™ and the TAKEDA Logo® are trademarks of Takeda Pharmaceutical Company Limited, used under license.  \nRECENT MAJOR LABEL CHANGES  \nNone.  \nNot applicable sections or subsections are omitted from this Product Monograph. Remaining sections and subsections are not renumbered.  \nTABLE OF CONTENTS  \nRECENT MAJOR LABEL CHANGES ............................................................................ 2  \nTABLE OF CONTENTS.................................................................................................. 2  \nPART I: HEALTH PROFESSIONAL INFORMATION .................................................... 4  \n1 INDICATIONS ...................................................................................................... 4  \n1.1 Pediatrics ..................................................................................................... 5  \n1.2 Geriatrics ..................................................................................................... 5  \n2 CONTRAINDICATIONS ....................................................................................... 5  \n3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................ 5  \n4 DOSAGE AND ADMINISTRATION ..................................................................... 5  \n4.1 Dosing Considerations................................................................................. 5  \n4.2 Recommended Dose and Dosage Adjustment............................................ 6  \n4.3 Administration .............................................................................................. 6  \n4.5 Missed Dose ................................................................................................ 7  \n5 OVERDOSAGE .................................................................................................... 7  \n6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............. 8  \n7 WARNINGS AND PRECAUTIONS ...................................................................... 9  \n7.1 Special Populations ................................................................................... 14  \n7.1.1 Pregnant Women ................................................................................... 14  \n7.1.2 Breast-feeding ........................................................................................ 14  \n7.1.3 Pediatrics ............................................................................................... 14  \n7.1.4 Geriatrics ................................................................................................ 14  \n8 ADVERSE REACTIONS .................................................................................... 14  \n8.1 Adverse Reaction Overview ...................................................................... 14  \n8.2 Clinical Trial Adverse Reactions ................................................................ 15  \n8.5 Clinical Trial Adverse Reactions (Pediatrics) ............................................. 17  \n8.6 Post-Market Adverse Reactions ................................................................ 19  \n9 DRUG INTERACTIONS ..................................................................................... 19  \n9.2 Overview.................................................................................................... 19  \n9.3 Drug-Drug Interactions .............................................................................. 20  \n9.6 Drug-Laboratory Test In","cbCaioPvm0omspZJ","https://ap.wps.com/l/cbCaioPvm0omspZJ","pdf",840501,42,"English","# RECENT MAJOR LABEL CHANGES\n# TABLE OF CONTENTS\n# PART I: HEALTH PROFESSIONAL INFORMATION\n## 1 INDICATIONS\n## 2 CONTRAINDICATIONS\n## 3 SERIOUS WARNINGS AND PRECAUTIONS BOX\n## 4 DOSAGE AND ADMINISTRATION\n## 5 OVERDOSAGE\n## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING\n## 7 WARNINGS AND PRECAUTIONS\n## 8 ADVERSE REACTIONS\n## 9 DRUG INTERACTIONS\n## 10 CLINICAL PHARMACOLOGY\n## 11 STORAGE, STABILITY AND DISPOSAL\n# PART II: SCIENTIFIC INFORMATION\n## 13 PHARMACEUTICAL INFORMATION\n## 14 CLINICAL TRIALS\n## 16 NON-CLINICAL TOXICOLOGY\n# PATIENT MEDICATION INFORMATION","[{\"question\":\"What is ADdERALL XR indicated for?\",\"answer\":\"ADDERALL XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (6–12 years), adolescents (13–17 years), and adults (18 years or older).\"},{\"question\":\"What key sections does Part I include?\",\"answer\":\"Part I covers health professional information including indications, contraindications, serious warnings and precautions, dosage and administration, overdosage, warnings and precautions, adverse reactions, drug interactions, clinical pharmacology, and storage/stability/disposal.\"},{\"question\":\"Where can the patient medication information be found in the monograph?\",\"answer\":\"The table of contents shows a dedicated section titled \\\"PATIENT MEDICATION INFORMATION\\\" separate from Part I and Part II.\"}]","ADDERALL XR Product Monograph - Patient Medication Information | PDF",1791843575]